OncoCyte Corp (NASDAQ:OCX)
| 0.4612 Delayed Data As of Nov 25 |  -0.0148 / -3.11%Today’s Change | 0.35 Today|||52-Week Range 2.68 | -78.75% Year-to-Date |
Latest OCX News | Press Releases
| OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? Nov 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.48 |
| Today’s open | 0.47 |
| Day’s range | 0.46 - 0.47 |
| Volume | 1,900 |
| Average volume (3 months) | 339,226 |
| Market cap | $54.7M |
Data as of 12:58pm ET, 11/25/2022
Growth & Valuation
| Earnings growth (last year) | -57.69% |
| Earnings growth (this year) | +49.54% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +535.44% |
| P/E ratio | NM |
| Price/Sales | 24.97 |
| Price/Book | 0.65 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CKPTCheckpoint Therapeut... | 0.00 | 0.00% |
| ORTXOrchard Therapeutics... | 0.00 | 0.00% |
| HOOKHOOKIPA Pharma Inc | +0.03 | +3.00% |
| MBIOMustang Bio Inc | +0.04 | +7.71% |
Data as of 1:00pm ET, 11/25/2022
Financials
| Next reporting date | April 3, 2023 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $7.7M |
| Annual profit (last year) | -$64.1M |
| Net profit margin | -829.52% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Irvine, California |
Forecasts
